Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients

Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases in platelet activation proces...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Cardiovasc Med
Main Authors: Tullemans, Bibian M. E., Nagy, Magdolna, Sabrkhany, Siamack, Griffioen, Arjan W., oude Egbrink, Mirjam G. A., Aarts, Maureen, Heemskerk, Johan W. M., Kuijpers, Marijke J. E.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2018
Assuntos:
Cardiovascular Medicine
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6232667/
https://ncbi.nlm.nih.gov/pubmed/30460241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2018.00142
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares